Results 71 to 80 of about 423,879 (287)

Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2021
Background: Hyperuricemia is very common in patients with chronic kidney disease (CKD); the role of hyperuricemia in the occurrence and progression of kidney disease remains an interesting and unresolved issue for nephrologists, and whether urate ...
Xiang Liu, Xiang Liu, Yuxuan Qiu, Yuxuan Qiu, Duohui Li, Jiaxing Tan, Xiuping Liang, Wei Qin   +7 more
doaj   +1 more source

Does the initiation of urate lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review [PDF]

, 2016
Objectives: To systematically review the literature on effect of initiating urate lowering treatment (ULT) during an acute attack of gout on duration of index attack and persistence on ULT.
A. Abhishek, Adrian Jones, D Khanna, EM Hill, Fatma Eminaga, Jonathan Le-Carratt, KM Jordan, PP Khanna, R Seth, RC Fraser, TH Taylor, W Zhang, X Feng   +12 more
core   +2 more sources

Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]

Journal of General Internal Medicine, 2017
Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie, Moreau, Perrine, Maruani, Annabel, Maisonneuve, Hubert, Giraudeau, Bruno, Fournier, Jean-Pascal   +5 more
openaire   +4 more sources

Prediction of renal and cardiometabolic outcomes in gout during urate‐lowering therapy by sonography

International Journal of Rheumatic Diseases, 2023
To assess whether the extent of monosodium urate (MSU) crystal deposition estimated by ultrasound could predict renal and cardiometabolic events during urate‐lowering therapy (ULT).
I. Calabuig, A. Marty-Ané, L. Norberciak, J. Budzik, Julie Legrand, A. Martínez-Sanchis, Tristan Pascart, M. Andrés   +7 more
semanticscholar   +1 more source

The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials

Advances in Rheumatology, 2022
Objective The objective was to evaluate whether initiation of urate-lowering treatment (ULT) during an acute gout flare prolonged the current episode.
Ertao Jia, Xiaoling Yao, Hongling Geng, Li Zhong, Jingjing Xie, Yuya Xiao, Yubao Jiang, Xia Qiu, Min Xiao, Yanying Zhang, Dabin Tang, Jiaxin Wei, Jianyong Zhang   +12 more
doaj   +1 more source

What makes gouty inflammation so variable? [PDF]

, 2017
Acute gout arthritis flares contribute dominantly to gout-specific impaired health-related quality of life, representing a progressively increasing public health problem.
Terkeltaub, Robert
core   +2 more sources

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, EarlyView.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Losartan/Hydrochlorothiazide Combination Therapy Surpasses High-dose Angiotensin Receptor Blocker in the Reduction of Morning Home Blood Pressure in Patients with Morning Hypertension [PDF]

, 2012
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone.
Hanayama, Yoshihisa, Makino, Hirofumi, Nakamura, Yoshio, Uchida, Haruhito Adam   +3 more
core   +1 more source

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials

HERALD of North-Western State Medical University named after I.I. Mechnikov
The presented study has been carried out to identify the effect of urate-lowering therapy with xanthine oxidase inhibitors on glomerular filtration rate and serum uric acid in patients with asymptomatic hyperuricemia and chronic kidney disease.
V. I. Mazurov, Sergey A. Sayganov, A. I. Martynov, R. A. Bashkinov, I. Gaydukova, K. V. Sapozhnikov, D. G. Tolkacheva, N. Sableva, Alexandra Yu. Tsinzerling   +8 more
semanticscholar   +1 more source